Is Centene Stock Outperforming the Dow?
Saint Louis, Missouri-based Centene Corporation (CNC) is a healthcare enterprise that provides programs and services to underinsured, uninsured families, and commercial organizations. Valued at a market cap of $29.4 billion, Centene is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and Centene fits the label perfectly, with its market cap exceeding this threshold. The company benefits from strong government contracts, diversified revenue streams, and a focus on cost-effective healthcare solutions. Additionally, Centene’s strategic acquisitions and expansions have strengthened its market position, while its commitment to digital transformation and value-based care enhances operational efficiency and customer experience. With a focus on innovation and growth, Centene continues to expand its influence in the managed healthcare sector.
Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas
Shares of Centene are currently down 26.5% from its 52-week high of $80.59, reached on Sep. 3. It has gained 2.5% over the past three months, outpacing the broader Dow Jones Industrials Average’s ($DOWI) 3.7% dip over the same time frame.
However, in the longer term, CNC stock has declined 21.5% over the past 52 weeks, considerably lagging behind DOWI’s 8.1% rise.
To confirm its bearish trend, Centene has been trading below its 200-day moving average since October and has remained under its 50-day moving average since early February, with slight fluctuations.
On Feb. 4, shares of Centene plummeted 5.5% after its Q4 earnings release, despite delivering better-than-expected Q4 adjusted EPS of $0.80 and revenue of $40.8 billion. Moreover, the bottom line climbed 77.8% year over year, while the top line improved by 3.4% annually. While total membership grew by 4.1% annually, Medicaid membership saw a notable decline of 10.1% from the previous year's quarter. Further contributing to the negative market reaction, service revenues fell by 29.7% year over year, raising concerns among investors despite the company's overall revenue growth.
Centene has considerably lagged behind its rival, The Cigna Group’s (CI) 10% decline over the past 52 weeks.
Wall Street analysts remain moderately optimistic about CNC stock's potential. The stock has a consensus rating of “Moderate Buy” from the 17 analysts covering it, and the mean price target of $77.41 suggests 30.7% premium to its current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
